摘要
目的探讨MCT1、CD147在人胶质瘤中的表达及其与预后的相关性,分析其作为胶质瘤预后判断指标及药物治疗靶点的可能性。方法本文采用实时荧光定量PCR和western blotting方法检测MCT1和CD147在不同级别胶质瘤及正常组织中的表达情况,并利用生存曲线对患者的生存预后进行分析。结果 MCT1和CD47在人胶质瘤患者组织中均高表达,且高级别胶质瘤患者MCT1和CD147表达与低级别胶质瘤患者差异有统计学意义(P<0.05),低级别胶质瘤患者MCT1和CD147与正常组织表达差异统计学意义(P<0.05)。不同级别胶质瘤患者与正常对照组MCT1和CD147表达生存相关曲线差异有统计学意义(P<0.05)。结论 MCT1和CD47是神经胶质瘤恶性程度的重要标志物,且二者可以作为胶质瘤预后判断的指标参考及药物治疗的靶点。
Objective To investigate the expression and prognostic significance of MCT1, CD147 in human gliomas and analyze the possibility of glioma prognosis as drug targets. Methods The expression of CD147 and MCT1 were detected by re- al-time PCR and Western blotting in different grade of glioma and normal tissues. And the prognosis of patients with survival curve was also analyzed. Results The expression of MCT1 and CD47 in human glioma patients showed high density. And the expression of MCT1 and CD147 in high grade glioma was significantly different with that in low level grade glioma （P^0.05）. the expression of MCT1 and CD147 in different grades of glioma patients and normal control group had significant difference in survival curve. Conclusion MCT1 and CD47 are important signs of malignancy of neuro-glioma, and the two dictators can be used as a target for drug treatment and judging the prognosis of it.
出处
《中国实用神经疾病杂志》
2014年第1期1-3,共3页
Chinese Journal of Practical Nervous Diseases
